@article {2235, title = {Safety Assessment of Oral Lysiphyllum strychnifolium Aqueous Extract in Healthy Volunteers}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {February 2024}, pages = {235-240}, type = {Research Article}, chapter = {235}, abstract = {

Background: Lysiphyllum strychnifolium (LS), widely known as Ya nang daeng in Thailand, is a traditional herbal remedy that has long been used to promote health and treat diverse health conditions, especially detoxification, by alleviating the severity of symptoms and lowering the risks associated with toxic exposures. Although it is extensively used in Thailand, human safety studies have been lacking. Thus, this study aimed to examine the safety of using LS capsules in healthy participants through a Phase I clinical trial. Objective: This study aimed to investigate the safety of aqueous extract of LS in twenty-four healthy Thai participants. Method: The participants were received 1,000 mg of LS aqueous extract each morning before their meals for seven days. All participants were examined safety assessment including history taking, physical examination, and laboratory tests at day 0, 8 and 14 (follow-up). Results: The findings showed that there were no significant side effects or abnormalities found during the history taking, physical examination, or laboratory evaluation. Particularly, when compared to baseline, participants who received LS experienced statistically significant reductions in blood sugar, triglyceride, LDL cholesterol, and creatinine (P \< 0.05), but still within normal ranges. Conclusions: Dietary supplementation with 1,000 mg of LS aqueous extract per day may have a beneficial effect on blood sugar and cholesterol management while remaining safe for healthy people.

}, keywords = {Clinical study, Healthy volunteers, Lysiphyllum strychnifolium, Safety, Yanang Daeng}, doi = {10.5530/pj.2024.16.34}, author = {Piracha Jumpa-ngern and Parunkul Tungsukruthai and Chuntida Kamalashiran and Somboon Kietinun and Kesara Na- Bangchang and Kusuma Sriyakul} } @article {2135, title = {The Investigation of The Network Pharmacology and Mechanism of Action of Centella Asiatica Extract on The Atopic Dermatitis Model}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {October 2023}, pages = {881-890}, type = {Research Article}, chapter = {881}, abstract = {

Background: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin condition which has a negative impact on children health. The well-known medicinal plant Centella asiatica extract (CE) is used in herbal skin care products to produce various pharmacological effects in dermatology. However, the molecular target of CE in suppressing inflammatory is largely unknown. Objective: the aim of this study was to examine anti-inflammatory properties and network pharmacology of CE in lipopolysaccharide (LPS)- induced AD in vitro model. Method: RAW264.7 cells were pre-treated with CE and then were stimulated with LPS and then were investigated cell viability, NO production, and the levels of pro-inflammatory mediators. In addition, the Search Tool for Retrieval of Interacting Genes (STRING), SwissTargetPrediction and the Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to construct the defined mechanism of action and network pharmacology. Results: CE showed the potent inhibitory effects on LPS-induced NO. In addition, CE significantly suppressed the expression of iNOS and COX-2, as well as the production of IL-2, IL-6, IL-10, and TNF- α. Furthermore, the network pharmacological analysis revealed the potential role of CE in biological processes such as regulating JAK/STATs pathway and inhibiting proinflammatory cytokines both of which were linked to AD pathogenesis. Conclusion: Our findings confirm our hypothesis that CE could be developed as a therapeutic therapy for atopic dermatitis due to its pharmacological action and signaling mechanism in the modulation of allergic skin inflammation.

}, keywords = {Atopic dermatitis, Centella asiatica, Network pharmacology, Skin inflammation.}, doi = {10.5530/pj.2023.15.168}, author = {Sucharat Tungsukruthai and Runtikan Pochairach and Aungkana Krajarng and Piracha Jumpa-ngern and Parunkul Tungsukruthai} }